STOCK TITAN

MiNK Therapeutics (INKT) EPS by Year

INKT NASDAQ

MiNK Therapeutics, Inc. lost $2.93 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $2.23 per diluted share. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters MiNK Therapeutics, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$2.93
YoY n/m
5Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

INKT EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
EPS (Diluted)-$2.23-$2.93n/m-$2.86n/m-$6.54n/m-$8.30n/m-$11.60n/m-$6.70

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

INKT EPS (Diluted) by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
EPS (Diluted)-$0.50n/m-$0.62n/m-$0.57n/m-$0.54n/m-$0.65n/m-$1.06n/m-$0.70n/m-$0.62n/m-$0.46n/m-$0.73n/m-$1.10n/m-$1.50n/m

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More MiNK Therapeutics, Inc. financials

Frequently Asked Questions

MiNK Therapeutics, Inc. lost $2.93 per diluted share in fiscal year 2025.

MiNK Therapeutics, Inc. (INKT) reported a loss of $2.86 per diluted share in fiscal year 2024 and a loss of $2.93 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

MiNK Therapeutics, Inc. (INKT) reported a loss of $2.23 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 6 fiscal years this page covers, MiNK Therapeutics, Inc. (INKT) diluted earnings per share went from -$6.70 in fiscal year 2020 to -$2.93 in fiscal year 2025.

MiNK Therapeutics, Inc. (INKT) reported -$0.50 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what MiNK Therapeutics, Inc. (INKT) reported on that line in every period on record.